Macro Tsimmis

intelligently hedged investment

Élan (ELN) update #11

Posted by intelledgement on Thu, 24 Apr 08

Élan (ELN), our major league biotech company, announced 1Q08 financial results today and the impact of increased tysabri sales is reflected clearly. Y-O-Y sales increased from $168MM to $207MM (including $160MM of tysabri sales, up from $41MM a year ago) and EBITA improved from a loss of $38MM to a loss of $33MM.

Management now project revenues approaching $1B for 2008 overall (up from $759MM in 2007) and reduced losses throughout the year.


Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: